\-\ Texto\\:\\ \ \(0\)\
\-\ vitals\\-\\ bp\\:\\ 104\\/69\\ pulse\\:\\ 135\\ bpm\\ respiratory\\ rate\\:\\ 36\\ breaths\\/min\\ spo2\\:\\ 99\\%\\ on\\ room\\ air\ \(0\)\
\-\ constitutional\\:\\ she\\ appears\\ well\\-developed\\ and\\ well\\-nourished\\.\\ she\\ is\\ active\\.\ \(0\)\
\-\ nose\\:\\ firm\\ mass\\ on\\ the\\ left\\ nasal\\ ala\\,\\ with\\ obstruction\\ of\\ the\\ left\\ nasal\\ airway\\.\\ mass\\ measures\\ 1\\-2\\ cm\\ and\\ extends\\ toward\\ cheek\\.\\ no\\ fluctuance\\.\\ no\\ changes\\ in\\ overlying\\ skin\\.no\\ mucosal\\ edema\\,\\ rhinorrhea\\,\\ nasal\\ discharge\\ or\\ congestion\\.\\ no\\ foreign\\ body\\ in\\ the\\ right\\ nostril\\.\\ no\\ foreign\\ body\\ in\\ the\\ left\\ nostril\\.\ \(0\)\
\-\ she\\ has\\ no\\ cervical\\ adenopathy\\.\ \(0\)\
\-\ patient\\ was\\ given\\ chemotherapy\\,\\ radiation\\,\\ and\\ had\\ surgical\\ excision\\ of\\ mass\\.\ \(0\)\
\-\ solid\\ left\\ nasal\\ mass\\ which\\ enhances\\.\\ would\\ favor\\ a\\ solid\\ neoplasm\\ such\\ as\ \(0\)\
\-\ rhabdomyosarcoma\\.\ \(6\)\
\-\ alveolar\\ rhabdomyosarcoma\ \(1\)\
\-\ vascular\\ anomaly\\ \\(hemangioma\\)\\ vs\\ benign\\ fibroma\\ vs\\ rhabdomyosarcoma\\ vs\\ dermoid\ \(0\)\
\-\ 8\\ month\\ old\\ who\\ was\\ noted\\ to\\ have\\ a\\ bump\\ on\\ her\\ left\\ nostril\\ about\\ 3\\ months\\ ago\\.\\ the\\ mass\\ has\\ grown\\ fairly\\ quickly\\ otherwise\\.\\ she\\ has\\ some\\ mild\\ nasal\\ congestion\\ and\\ mouth\\ breathing\\ over\\ the\\ last\\ few\\ weeks\\.\\ she\\ is\\ eating\\ and\\ gaining\\ weight\\ well\\.\\ she\\ was\\ born\\ at\\ 37\\ weeks\\.\\ she\\ had\\ no\\ complications\\ during\\ pregnancy\\ or\\ birth\\.\\ she\\ is\\ meeting\\ all\\ milestones\\.\\ she\\ passed\\ her\\ newborn\\ hearing\\ screen\\.\\ ros\\ negative\\.\ \(0\)\
\-\ rhabdomyosarcoma\\â\\€\\™s\\ are\\ malignant\\ tumors\\ of\\ mesenchymal\\ origin\\ that\\ are\\ from\\ precursor\\ skeletal\\ muscle\\ cells\\.\\ these\\ tumors\\ can\\ arise\\ in\\ many\\ different\\ locations\\ and\\ clinically\\ present\\ as\\ different\\ tissue\\ types\\,\\ including\\ fat\\,\\ muscle\\ and\\ soft\\ tissue\\.\\ unfortunately\\,\\ the\\ prognosis\\ of\\ these\\ tumors\\ is\\ extremely\\ poor\\,\\ especially\\ with\\ metastasis\\.\\ fortunately\\ these\\ tumors\\ are\\ relatively\\ rare\\ and\\ the\\ prognosis\\ has\\ been\\ steadily\\ improving\\ for\\ non\\-metastatic\\ disease\\.\\ there\\ are\\ 3\\ different\\ histological\\ subtypes\\ of\\ this\\ tumor\\;\\ alveolar\\,\\ embryonal\\,\\ and\\ pleomorphic\\/anaplastic\\.\\ \ \(0\)\
\-\ rhabdomyosarcoma\\â\\€\\™s\\ are\\ the\\ most\\ common\\ type\\ of\\ soft\\ tissue\\ tumors\\ in\\ the\\ pediatric\\ population\\,\\ but\\ are\\ still\\ rare\\ tumors\\ in\\ general\\.\\ they\\ have\\ a\\ 3\\ to\\ 4\\ percent\\ prevalence\\ rate\\ for\\ pediatric\\ patients\\ overall\\,\\ with\\ two\\-thirds\\ of\\ cases\\ diagnosed\\ under\\ the\\ age\\ of\\ six\\ \\[1\\]\\.\\ there\\ is\\ a\\ race\\ predilection\\ with\\ higher\\ incidence\\ in\\ blacks\\ than\\ whites\\ and\\ lower\\ incidence\\ in\\ asians\\ than\\ whites\\.\\ there\\ also\\ seems\\ to\\ be\\ male\\ predominance\\ with\\ a\\ male\\ to\\ female\\ ratio\\ that\\ is\\ 1\\.3\\-1\\.5\\.\\ these\\ tumors\\ can\\ be\\ seen\\ in\\ many\\ locations\\ throughout\\ the\\ body\\,\\ however\\ the\\ most\\ common\\ locations\\ are\\ the\\ head\\ and\\ neck\\ region\\ \\(36\\%\\)\\,\\ genitourinary\\ tract\\ \\(23\\%\\)\\,\\ extremities\\ \\(19\\%\\)\\ and\\ others\\ \\(22\\%\\)\\ \\[2\\]\\.\ \(0\)\
\-\ of\\ the\\ 3\\ different\\ histological\\ subtypes\\,\\ the\\ embryonal\\ is\\ the\\ most\\ common\\ \\(70\\-80\\%\\)\\,\\ followed\\ by\\ alveolar\\ \\(15\\-20\\%\\)\\,\\ and\\ pleomorphic\\/anaplastic\\ subtypes\\ are\\ extremely\\ rare\\ \\[3\\]\\.\\ in\\ addition\\ to\\ the\\ histological\\ features\\ of\\ the\\ tumor\\,\\ the\\ genetic\\ and\\ molecular\\ features\\ are\\ analyzed\\ for\\ further\\ management\\ and\\ prognostic\\ value\\.\\ each\\ histological\\ subtype\\ has\\ its\\ own\\ molecular\\ component\\.\\ for\\ the\\ embryonal\\ subtype\\,\\ the\\ cells\\ can\\ by\\ analyzed\\ for\\ a\\ myod1\\ mutation\\ \\(a\\ poorer\\ outcome\\)\\.\\ the\\ alveolar\\ subtype\\ can\\ have\\ a\\ translocation\\ between\\ the\\ foxo1\\ and\\ pax3\\ or\\ pax7\\ genes\\.\\ studies\\ have\\ shown\\ that\\ a\\ positive\\ foxo1\\ translocation\\ could\\ have\\ a\\ worse\\ prognosis\\ \\[4\\]\\.\\ in\\ addition\\ to\\ molecular\\ analysis\\,\\ prognosis\\ is\\ determined\\ by\\ the\\ typical\\ factors\\ of\\ most\\ neoplasms\\,\\ stage\\ and\\ grade\\.\\ however\\,\\ with\\ rhabdomyosarcoma\\â\\€\\™s\\ there\\ are\\ some\\ additional\\ prognostic\\ factors\\ that\\ are\\ looked\\ at\\.\\ histologic\\ subtype\\ is\\ a\\ factor\\ that\\ is\\ used\\ for\\ prognosis\\.\\ pleomorphic\\ subtypes\\ have\\ the\\ best\\ prognosis\\ of\\ the\\ 3\\ major\\ subtypes\\ \\(75\\%\\ 5\\-year\\ survival\\ rate\\)\\ followed\\ by\\ embryonal\\ \\(66\\%\\ 5\\-year\\ survival\\ rate\\)\\ and\\ then\\ alveolar\\ \\(54\\%\\ 5\\-year\\ survival\\ rate\\)\\.\\ \\ \ \(0\)\
\-\ a\\ high\\ degree\\ of\\ suspension\\ is\\ required\\ to\\ make\\ the\\ diagnosis\\ for\\ a\\ rhabdomyosarcoma\\.\\ majority\\ cases\\ sporadic\\,\\ but\\ there\\ are\\ some\\ associations\\ with\\ genetic\\ syndromes\\,\\ such\\ as\\,\\ li\\-fraumeni\\,\\ beckwith\\-wiedemann\\,\\ and\\ costello\\ syndromes\\ \\[3\\]\\.\\ signs\\ of\\ rhabdomyosarcoma\\ can\\ include\\,\\ lump\\ or\\ swelling\\ that\\ doesn\\â\\€\\™t\\ go\\ away\\ or\\ grows\\ rapidly\\,\\ bulging\\ of\\ the\\ eye\\,\\ headache\\,\\ and\\ epistaxis\\.\\ since\\ the\\ presentation\\ can\\ be\\ non\\-specific\\,\\ further\\ investigation\\ includes\\,\\ doppler\\ ultrasound\\ for\\ assessment\\ of\\ flow\\,\\ biopsy\\ of\\ the\\ mass\\,\\ and\\ mri\\ is\\ preferable\\ in\\ head\\ and\\ neck\\ tumors\\,\\ paraspinal\\ tumors\\,\\ limb\\ and\\ genitourinary\\ primaries\\ and\\ ct\\ is\\ recommended\\ for\\ tumors\\ in\\ the\\ chest\\ and\\ abdomen\\.\\ after\\ appropriate\\ work\\ up\\ and\\ diagnosis\\,\\ proper\\ management\\ can\\ be\\ initiated\\.\\ \ \(0\)\
\-\ references\\:\ \(0\)\
\-\ 1\\.\\	ries\\ lag\\,\\ harkins\\ d\\,\\ krapcho\\ m\\,\\ et\\ al\\.\\ seer\\ cancer\\ statistics\\ review\\ 1975\\-2011\\,\\ national\\ cancer\\ institute\\.\\ bethesda\\,\\ md\\.\\ https\\:\\/\\/seer\\.cancer\\.gov\\/archive\\/csr\\/1975\\_2011\ \(0\)\
\-\ 2\\.\\	sultan\\ i\\,\\ qaddoumi\\ i\\,\\ yaser\\ s\\,\\ et\\ al\\.\\ comparing\\ adult\\ and\\ pediatric\\ rhabdomyosarcoma\\ in\\ the\\ surveillance\\,\\ epidemiology\\ and\\ end\\ results\\ program\\,\\ 1973\\ to\\ 2005\\:\\ an\\ analysis\\ of\\ 2\\,600\\ patients\\.\\ j\\ clin\\ oncol\\.\\ 2009\\;27\\:3391\\â\\€\\“7\\.\ \(0\)\
\-\ 3\\.\\	panda\\ sp\\,\\ chinnaswamy\\ g\\,\\ vora\\ t\\,\\ et\\ al\\.\\ diagnosis\\ and\\ management\\ of\\ rhabdomyosarcoma\\ in\\ children\\ and\\ adolescents\\:\\ icmr\\ consensus\\ document\\.\\ indian\\ j\\ ped\\.\\ may\\ 2017\\:\\ 84\\:\\ 393\\-402\\.\\ \ \(0\)\
\-\ 4\\.\\	skapek\\ sx\\,\\ anderson\\ j\\,\\ barr\\ fg\\,\\ et\\ al\\.\\ pax\\-foxo1\\ fusion\\ status\\ drives\\ unfavorable\\ outcome\\ for\\ children\\ with\\ rhabdomyosarcoma\\:\\ a\\ children\\'s\\ oncology\\ group\\ report\\.\\ pediatr\\ blood\\ cancer\\.\\ 2013\\;60\\:1411\\â\\€\\“7\\.\ \(0\)\
\-\ Keywords\\ by\\ value\\:\\ \ \(0\)\
\-\ rhabdomyosarcoma\\:\\ 0\\.31554404707454775\ \(0\)\
\-\ tumors\\:\\ 0\\.20847508948731985\ \(0\)\
\-\ the\\:\\ 0\\.18665412944256302\ \(0\)\
\-\ and\\:\\ 0\\.17572470536310214\ \(0\)\
\-\ subtypes\\:\\ 0\\.1670831696082767\ \(0\)\
\-\ she\\:\\ 0\\.1518668204807609\ \(0\)\
\-\ prognosis\\:\\ 0\\.14967143919690384\ \(0\)\
\-\ alveolar\\:\\ 0\\.14875644048438594\ \(0\)\
\-\ foxo1\\:\\ 0\\.13599743980684914\ \(0\)\
\-\ subtype\\:\\ 0\\.13366653568662137\ \(0\)\
\-\ embryonal\\:\\ 0\\.13278296022133415\ \(0\)\
\-\ nasal\\:\\ 0\\.1292152115624589\ \(0\)\
\-\ are\\:\\ 0\\.1290752178629774\ \(0\)\
\-\ nostril\\:\\ 0\\.12566408393148013\ \(0\)\
\-\ histological\\:\\ 0\\.12501364218781646\ \(0\)\
\-\ rate\\:\\ 0\\.1074014797281423\ \(0\)\
\-\ molecular\\:\\ 0\\.10698804232875904\ \(0\)\
\-\ in\\:\\ 0\\.10577593448984068\ \(0\)\
\-\ of\\:\\ 0\\.10539900084071552\ \(0\)\
\-\ can\\:\\ 0\\.10412800284521284\ \(0\)\
\-\ different\\:\\ 0\\.1037697260029359\ \(0\)\
\-\ is\\:\\ 0\\.10091802947796376\ \(0\)\
\-\ seer\\:\\ 0\\.09066495987123277\ \(0\)\
\-\ al\\:\\ 0\\.09009256230836184\ \(0\)\
\-\ locations\\:\\ 0\\.08893325233647571\ \(0\)\
\-\ et\\:\\ 0\\.08882233525093827\ \(0\)\
\-\ pleomorphic\\:\\ 0\\.08605746738396756\ \(0\)\
\-\ for\\:\\ 0\\.0859165500154716\ \(0\)\
\-\ have\\:\\ 0\\.08496426825436844\ \(0\)\
\-\ survival\\:\\ 0\\.08299473300727025\ \(0\)\
\-\ analyzed\\:\\ 0\\.0815583242404863\ \(0\)\
\-\ translocation\\:\\ 0\\.0815583242404863\ \(0\)\
\-\ pediatric\\:\\ 0\\.0761216785699687\ \(0\)\
\-\ cancer\\:\\ 0\\.07552351866779325\ \(0\)\
\-\ that\\:\\ 0\\.07380832357854229\ \(0\)\
\-\ whites\\:\\ 0\\.07372217176022337\ \(0\)\
\-\ children\\:\\ 0\\.06967948581490101\ \(0\)\
\-\ genitourinary\\:\\ 0\\.06639148011066708\ \(0\)\
\-\ prognostic\\:\\ 0\\.06639148011066708\ \(0\)\
\-\ mass\\:\\ 0\\.06496600369421994\ \(0\)\
\-\ vs\\:\\ 0\\.06487663981465809\ \(0\)\
\-\ has\\:\\ 0\\.06473964097792172\ \(0\)\
\-\ no\\:\\ 0\\.06452607828385039\ \(0\)\
\-\ rare\\:\\ 0\\.06419748845013193\ \(0\)\
\-\ these\\:\\ 0\\.06402941697589667\ \(0\)\
\-\ management\\:\\ 0\\.06281507340013591\ \(0\)\
\-\ outcome\\:\\ 0\\.06040670717312831\ \(0\)\
\-\ most\\:\\ 0\\.059009840327973684\ \(0\)\
\-\ syndromes\\:\\ 0\\.05828408228571861\ \(0\)\
\-\ extremely\\:\\ 0\\.05809477013294071\ \(0\)\
\-\ to\\:\\ 0\\.05669287393601311\ \(0\)\
\-\ there\\:\\ 0\\.0563952395950099\ \(0\)\
\-\ congestion\\:\\ 0\\.05606635057188482\ \(0\)\
\-\ body\\:\\ 0\\.05596731556836628\ \(0\)\
\-\ genetic\\:\\ 0\\.05591461346393297\ \(0\)\
\-\ some\\:\\ 0\\.053506326248748425\ \(0\)\
\-\ analysis\\:\\ 0\\.052722291800817236\ \(0\)\
\-\ foreign\\:\\ 0\\.05139517836880591\ \(0\)\
\-\ or\\:\\ 0\\.04930649077965312\ \(0\)\
\-\ incidence\\:\\ 0\\.04880236110235316\ \(0\)\
\-\ left\\:\\ 0\\.04834831931097457\ \(0\)\
\-\ common\\:\\ 0\\.04822740869590117\ \(0\)\
\-\ by\\:\\ 0\\.04815054295313292\ \(0\)\
\-\ factors\\:\\ 0\\.04795601277131424\ \(0\)\
\-\ 36\\:\\ 0\\.04692918162213641\ \(0\)\
\-\ be\\:\\ 0\\.045996426399495575\ \(0\)\
\-\ addition\\:\\ 0\\.04588814608037642\ \(0\)\
\-\ features\\:\\ 0\\.04561732312407651\ \(0\)\
\-\ myod1\\:\\ 0\\.045332479935616385\ \(0\)\
\-\ pax3\\:\\ 0\\.045332479935616385\ \(0\)\
\-\ pax7\\:\\ 0\\.045332479935616385\ \(0\)\
\-\ costello\\:\\ 0\\.045332479935616385\ \(0\)\
\-\ ries\\:\\ 0\\.045332479935616385\ \(0\)\
\-\ harkins\\:\\ 0\\.045332479935616385\ \(0\)\
\-\ krapcho\\:\\ 0\\.045332479935616385\ \(0\)\
\-\ sultan\\:\\ 0\\.045332479935616385\ \(0\)\
\-\ qaddoumi\\:\\ 0\\.045332479935616385\ \(0\)\
\-\ yaser\\:\\ 0\\.045332479935616385\ \(0\)\
\-\ chinnaswamy\\:\\ 0\\.045332479935616385\ \(0\)\
\-\ vora\\:\\ 0\\.045332479935616385\ \(0\)\
\-\ icmr\\:\\ 0\\.045332479935616385\ \(0\)\
\-\ skapek\\:\\ 0\\.045332479935616385\ \(0\)\
\-\ fg\\:\\ 0\\.045332479935616385\ \(0\)\
\-\ many\\:\\ 0\\.044699262797617816\ \(0\)\
\-\ tissue\\:\\ 0\\.04461005625021168\ \(0\)\
\-\ with\\:\\ 0\\.04440504282888533\ \(0\)\
\-\ diagnosis\\:\\ 0\\.04408412241203412\ \(0\)\
\-\ cells\\:\\ 0\\.04368140230300524\ \(0\)\
\-\ solid\\:\\ 0\\.043463919062118904\ \(0\)\
\-\ fluctuance\\:\\ 0\\.04331760470438388\ \(0\)\
\-\ drives\\:\\ 0\\.04331760470438388\ \(0\)\
\-\ asians\\:\\ 0\\.04188802797716004\ \(0\)\
\-\ statistics\\:\\ 0\\.04188802797716004\ \(0\)\
\-\ bethesda\\:\\ 0\\.04188802797716004\ \(0\)\
\-\ panda\\:\\ 0\\.04188802797716004\ \(0\)\
\-\ well\\:\\ 0\\.04117677708311565\ \(0\)\
\-\ gaining\\:\\ 0\\.04077916212024315\ \(0\)\
\-\ suspension\\:\\ 0\\.04077916212024315\ \(0\)\
\-\ muscle\\:\\ 0\\.040256007454601624\ \(0\)\
\-\ poorer\\:\\ 0\\.03987315274592753\ \(0\)\
\-\ preferable\\:\\ 0\\.03987315274592753\ \(0\)\
\-\ primaries\\:\\ 0\\.03987315274592753\ \(0\)\
\-\ 1973\\:\\ 0\\.03987315274592753\ \(0\)\
\-\ barr\\:\\ 0\\.03987315274592753\ \(0\)\
\-\ ala\\:\\ 0\\.03910713273470936\ \(0\)\
\-\ blacks\\:\\ 0\\.03910713273470936\ \(0\)\
\-\ institute\\:\\ 0\\.03910713273470936\ \(0\)\
\-\ ped\\:\\ 0\\.03910713273470936\ \(0\)\
\-\ unfavorable\\:\\ 0\\.03910713273470936\ \(0\)\
\-\ precursor\\:\\ 0\\.0384435760187037\ \(0\)\
\-\ genes\\:\\ 0\\.0384435760187037\ \(0\)\
\-\ sp\\:\\ 0\\.0384435760187037\ \(0\)\
\-\ followed\\:\\ 0\\.03828430856051685\ \(0\)\
\-\ cases\\:\\ 0\\.03813218435301022\ \(0\)\
\-\ meeting\\:\\ 0\\.037858277514695025\ \(0\)\
\-\ steadily\\:\\ 0\\.037858277514695025\ \(0\)\
\-\ fortunately\\:\\ 0\\.0373347101617868\ \(0\)\
\-\ oncol\\:\\ 0\\.0373347101617868\ \(0\)\
\-\ indian\\:\\ 0\\.0373347101617868\ \(0\)\
\-\ anderson\\:\\ 0\\.0373347101617868\ \(0\)\
\-\ further\\:\\ 0\\.03692530999522795\ \(0\)\
\-\ associations\\:\\ 0\\.03686108588011169\ \(0\)\
\-\ such\\:\\ 0\\.03646803254580293\ \(0\)\
\-\ 135\\:\\ 0\\.03642870078747119\ \(0\)\
\-\ rhinorrhea\\:\\ 0\\.03642870078747119\ \(0\)\
\-\ milestones\\:\\ 0\\.03642870078747119\ \(0\)\
\-\ looked\\:\\ 0\\.03642870078747119\ \(0\)\
\-\ comparing\\:\\ 0\\.03642870078747119\ \(0\)\
\-\ race\\:\\ 0\\.036030945059771995\ \(0\)\
\-\ grows\\:\\ 0\\.036030945059771995\ \(0\)\
\-\ lag\\:\\ 0\\.036030945059771995\ \(0\)\
\-\ grown\\:\\ 0\\.03566268077625301\ \(0\)\
\-\ consensus\\:\\ 0\\.03566268077625301\ \(0\)\
\-\ sx\\:\\ 0\\.03566268077625301\ \(0\)\
\-\ her\\:\\ 0\\.03541876989061145\ \(0\)\
\-\ epistaxis\\:\\ 0\\.03531983493055429\ \(0\)\
\-\ pediatr\\:\\ 0\\.03531983493055429\ \(0\)\
\-\ epidemiology\\:\\ 0\\.03499912406024735\ \(0\)\
\-\ program\\:\\ 0\\.03499912406024735\ \(0\)\
\-\ national\\:\\ 0\\.03469786250541046\ \(0\)\
\-\ document\\:\\ 0\\.03469786250541046\ \(0\)\
\-\ neck\\:\\ 0\\.034680873596671415\ \(0\)\
\-\ 2017\\:\\ 0\\.034413825556238675\ \(0\)\
\-\ as\\:\\ 0\\.034163577697698407\ \(0\)\
\-\ doesn\\:\\ 0\\.034145149651011376\ \(0\)\
\-\ weeks\\:\\ 0\\.03397741856271132\ \(0\)\
\-\ favor\\:\\ 0\\.03389025820333045\ \(0\)\
\-\ bump\\:\\ 0\\.03389025820333045\ \(0\)\
\-\ adolescents\\:\\ 0\\.03389025820333045\ \(0\)\
\-\ head\\:\\ 0\\.03381314064865627\ \(0\)\
\-\ however\\:\\ 0\\.033555816565318614\ \(0\)\
\-\ spo2\\:\\ 0\\.03341663392165534\ \(0\)\
\-\ cheek\\:\\ 0\\.03341663392165534\ \(0\)\
\-\ quickly\\:\\ 0\\.03341663392165534\ \(0\)\
\-\ ros\\:\\ 0\\.03319574005533354\ \(0\)\
\-\ mesenchymal\\:\\ 0\\.03319574005533354\ \(0\)\
\-\ improving\\:\\ 0\\.03319574005533354\ \(0\)\
\-\ investigation\\:\\ 0\\.03319574005533354\ \(0\)\
\-\ seems\\:\\ 0\\.03298424882901484\ \(0\)\
\-\ predilection\\:\\ 0\\.03278139234641356\ \(0\)\
\-\ constitutional\\:\\ 0\\.03239895032500617\ \(0\)\
\-\ sporadic\\:\\ 0\\.032218228817796665\ \(0\)\
\-\ than\\:\\ 0\\.03213783089898735\ \(0\)\
\-\ bpm\\:\\ 0\\.03204384974126186\ \(0\)\
\-\ own\\:\\ 0\\.03204384974126186\ \(0\)\
\-\ patients\\:\\ 0\\.03189309271120562\ \(0\)\
\-\ mutation\\:\\ 0\\.031875382972097945\ \(0\)\
\-\ histologic\\:\\ 0\\.031712440710183455\ \(0\)\
\-\ predominance\\:\\ 0\\.03140175869042283\ \(0\)\
\-\ https\\:\\ 0\\.031253410546954116\ \(0\)\
\-\ prevalence\\:\\ 0\\.030969373597782332\ \(0\)\
\-\ go\\:\\ 0\\.030969373597782332\ \(0\)\
\-\ proper\\:\\ 0\\.030969373597782332\ \(0\)\
\-\ initiated\\:\\ 0\\.030969373597782332\ \(0\)\
\-\ surveillance\\:\\ 0\\.030969373597782332\ \(0\)\
\-\ 2013\\:\\ 0\\.030969373597782332\ \(0\)\
\-\ eating\\:\\ 0\\.03057161787008314\ \(0\)\
\-\ 2009\\:\\ 0\\.03057161787008314\ \(0\)\
\-\ passed\\:\\ 0\\.030445806244874106\ \(0\)\
\-\ oncology\\:\\ 0\\.03032310139923425\ \(0\)\
\-\ soft\\:\\ 0\\.03018231681619119\ \(0\)\
\-\ bulging\\:\\ 0\\.030086423632636444\ \(0\)\
\-\ others\\:\\ 0\\.029860507740865433\ \(0\)\
\-\ fairly\\:\\ 0\\.029751288096877188\ \(0\)\
\-\ clin\\:\\ 0\\.029751288096877188\ \(0\)\
\-\ tumor\\:\\ 0\\.029653895357238783\ \(0\)\
\-\ lump\\:\\ 0\\.029644417445491903\ \(0\)\
\-\ was\\:\\ 0\\.029637274644774853\ \(0\)\
\-\ away\\:\\ 0\\.029437333575345975\ \(0\)\
\-\ 84\\:\\ 0\\.029437333575345975\ \(0\)\
\-\ screen\\:\\ 0\\.029238535315721605\ \(0\)\
\-\ unfortunately\\:\\ 0\\.029238535315721605\ \(0\)\
\-\ toward\\:\\ 0\\.029047385066470355\ \(0\)\
\-\ value\\:\\ 0\\.028863316106282098\ \(0\)\
\-\ nose\\:\\ 0\\.02868582246132252\ \(0\)\
\-\ fibroma\\:\\ 0\\.028514450521798726\ \(0\)\
\-\ airway\\:\\ 0\\.028430931013641594\ \(0\)\
\-\ ratio\\:\\ 0\\.028430931013641594\ \(0\)\
\-\ rapidly\\:\\ 0\\.028348792056614072\ \(0\)\
\-\ limb\\:\\ 0\\.028348792056614072\ \(0\)\
\-\ had\\:\\ 0\\.028246696177475477\ \(0\)\
\-\ but\\:\\ 0\\.028034935028029413\ \(0\)\
\-\ percent\\:\\ 0\\.02803317528594241\ \(0\)\
\-\ mouth\\:\\ 0\\.027957306731966485\ \(0\)\
\-\ newborn\\:\\ 0\\.027957306731966485\ \(0\)\
\-\ 99\\:\\ 0\\.027808958588497766\ \(0\)\
\-\ breathing\\:\\ 0\\.02773641286564468\ \(0\)\
\-\ assessment\\:\\ 0\\.02773641286564468\ \(0\)\
\-\ paraspinal\\:\\ 0\\.027594423384283556\ \(0\)\
\-\ make\\:\\ 0\\.027524921639325985\ \(0\)\
\-\ born\\:\\ 0\\.027063861950334698\ \(0\)\
\-\ determined\\:\\ 0\\.02700135428641776\ \(0\)\
\-\ 2005\\:\\ 0\\.026939623135317312\ \(0\)\
\-\ group\\:\\ 0\\.026939623135317312\ \(0\)\
\-\ each\\:\\ 0\\.026878649440777905\ \(0\)\
\-\ population\\:\\ 0\\.026818414839533386\ \(0\)\
\-\ pulse\\:\\ 0\\.026758901628107807\ \(0\)\
\-\ mucosal\\:\\ 0\\.02670009273158087\ \(0\)\
\-\ 54\\:\\ 0\\.02670009273158087\ \(0\)\
\-\ factor\\:\\ 0\\.026584522551573002\ \(0\)\
\-\ 66\\:\\ 0\\.026584522551573002\ \(0\)\
\-\ neoplasms\\:\\ 0\\.02641605578240909\ \(0\)\
\-\ types\\:\\ 0\\.026361145900408618\ \(0\)\
\-\ adult\\:\\ 0\\.026147379877181784\ \(0\)\
\-\ overall\\:\\ 0\\.02604384917916009\ \(0\)\
\-\ anomaly\\:\\ 0\\.025942431500733974\ \(0\)\
\-\ arise\\:\\ 0\\.025942431500733974\ \(0\)\
\-\ md\\:\\ 0\\.02584304231249178\ \(0\)\
\-\ hearing\\:\\ 0\\.025745602057997103\ \(0\)\
\-\ higher\\:\\ 0\\.025745602057997103\ \(0\)\
\-\ majority\\:\\ 0\\.025745602057997103\ \(0\)\
\-\ firm\\:\\ 0\\.025697589184402955\ \(0\)\
\-\ skeletal\\:\\ 0\\.025697589184402955\ \(0\)\
\-\ on\\:\\ 0\\.02568353337012993\ \(0\)\
\-\ six\\:\\ 0\\.025464246141401303\ \(0\)\
\-\ discharge\\:\\ 0\\.02541886414782575\ \(0\)\
\-\ doppler\\:\\ 0\\.025373892856656234\ \(0\)\
\-\ birth\\:\\ 0\\.02532932490088397\ \(0\)\
\-\ male\\:\\ 0\\.02524204668583719\ \(0\)\
\-\ still\\:\\ 0\\.02511229068039429\ \(0\)\
\-\ enhances\\:\\ 0\\.024986479055185248\ \(0\)\
\-\ end\\:\\ 0\\.02494523986615064\ \(0\)\
\-\ appropriate\\:\\ 0\\.024904340098157726\ \(0\)\
\-\ 75\\:\\ 0\\.024863774209545393\ \(0\)\
\-\ major\\:\\ 0\\.024783622572583965\ \(0\)\
\-\ degree\\:\\ 0\\.024783622572583965\ \(0\)\
\-\ origin\\:\\ 0\\.02440118055117658\ \(0\)\
\-\ component\\:\\ 0\\.024291960907188333\ \(0\)\
\-\ overlying\\:\\ 0\\.02414997142582721\ \(0\)\
\-\ 37\\:\\ 0\\.02414997142582721\ \(0\)\
\-\ few\\:\\ 0\\.024046079967432264\ \(0\)\
\-\ dermoid\\:\\ 0\\.023944316129432396\ \(0\)\
\-\ poor\\:\\ 0\\.023910852745340435\ \(0\)\
\-\ report\\:\\ 0\\.023877613198268352\ \(0\)\
\-\ adenopathy\\:\\ 0\\.023844594513604767\ \(0\)\
\-\ hemangioma\\:\\ 0\\.023844594513604767\ \(0\)\
\-\ fusion\\:\\ 0\\.023811793775642333\ \(0\)\
\-\ tract\\:\\ 0\\.02374683476229196\ \(0\)\
\-\ worse\\:\\ 0\\.02374683476229196\ \(0\)\
\-\ clinically\\:\\ 0\\.02355690232796141\ \(0\)\
\-\ under\\:\\ 0\\.023464590811068206\ \(0\)\
\-\ 23\\:\\ 0\\.023373962881077036\ \(0\)\
\-\ extends\\:\\ 0\\.02334411718319795\ \(0\)\
\-\ review\\:\\ 0\\.02334411718319795\ \(0\)\
\-\ room\\:\\ 0\\.02319751971572375\ \(0\)\
\-\ pregnancy\\:\\ 0\\.02319751971572375\ \(0\)\
\-\ measures\\:\\ 0\\.023111593187050177\ \(0\)\
\-\ work\\:\\ 0\\.023111593187050177\ \(0\)\
\-\ relatively\\:\\ 0\\.0230832780462863\ \(0\)\
\-\ last\\:\\ 0\\.023055123332109868\ \(0\)\
\-\ bp\\:\\ 0\\.022999287983348358\ \(0\)\
\-\ best\\:\\ 0\\.022808661562038254\ \(0\)\
\-\ general\\:\\ 0\\.022755513528579213\ \(0\)\
\-\ eye\\:\\ 0\\.022676842327281416\ \(0\)\
\-\ references\\:\\ 0\\.022599397220703744\ \(0\)\
\-\ stage\\:\\ 0\\.02257384809625355\ \(0\)\
\-\ respiratory\\:\\ 0\\.022548429658433282\ \(0\)\
\-\ recommended\\:\\ 0\\.022548429658433282\ \(0\)\
\-\ 19\\:\\ 0\\.022448036471044513\ \(0\)\
\-\ especially\\:\\ 0\\.022423251912140726\ \(0\)\
\-\ excision\\:\\ 0\\.022349631398808908\ \(0\)\
\-\ 22\\:\\ 0\\.02232533162540466\ \(0\)\
\-\ results\\:\\ 0\\.022088653858806855\ \(0\)\
\-\ includes\\:\\ 0\\.022042641550820075\ \(0\)\
\-\ shown\\:\\ 0\\.021974412189369404\ \(0\)\
\-\ additional\\:\\ 0\\.021974412189369404\ \(0\)\
\-\ typical\\:\\ 0\\.02190710695607032\ \(0\)\
\-\ complications\\:\\ 0\\.021710493865892817\ \(0\)\
\-\ extremities\\:\\ 0\\.021542027096728904\ \(0\)\
\-\ at\\:\\ 0\\.021413784451016642\ \(0\)\
\-\ about\\:\\ 0\\.02122131622642196\ \(0\)\
\-\ used\\:\\ 0\\.02122131622642196\ \(0\)\
\-\ active\\:\\ 0\\.021049615292640763\ \(0\)\
\-\ its\\:\\ 0\\.020975167551757882\ \(0\)\
\-\ throughout\\:\\ 0\\.020847508948731983\ \(0\)\
\-\ studies\\:\\ 0\\.020793786330805742\ \(0\)\
\-\ metastasis\\:\\ 0\\.020776007085510726\ \(0\)\
\-\ appears\\:\\ 0\\.02075829122446891\ \(0\)\
\-\ ago\\:\\ 0\\.020740638297346705\ \(0\)\
\-\ could\\:\\ 0\\.02061879311674818\ \(0\)\
\-\ diagnosed\\:\\ 0\\.020533554427200774\ \(0\)\
\-\ since\\:\\ 0\\.020533554427200774\ \(0\)\
\-\ grade\\:\\ 0\\.02038371512280292\ \(0\)\
\-\ cervical\\:\\ 0\\.020302382803835613\ \(0\)\
\-\ including\\:\\ 0\\.020286274868308248\ \(0\)\
\-\ they\\:\\ 0\\.020254214797368313\ \(0\)\
\-\ required\\:\\ 0\\.020238261994714103\ \(0\)\
\-\ otherwise\\:\\ 0\\.02020650921090032\ \(0\)\
\-\ malignant\\:\\ 0\\.02020650921090032\ \(0\)\
\-\ chemotherapy\\:\\ 0\\.020128003727300812\ \(0\)\
\-\ would\\:\\ 0\\.020066080262349104\ \(0\)\
\-\ then\\:\\ 0\\.020066080262349104\ \(0\)\
\-\ biopsy\\:\\ 0\\.019869997711195114\ \(0\)\
\-\ obstruction\\:\\ 0\\.019855230111146958\ \(0\)\
\-\ signs\\:\\ 0\\.019811188814668177\ \(0\)\
\-\ status\\:\\ 0\\.01978204331317732\ \(0\)\
\-\ weight\\:\\ 0\\.019767534415982595\ \(0\)\
\-\ headache\\:\\ 0\\.01954097466650674\ \(0\)\
\-\ presentation\\:\\ 0\\.01951336740795002\ \(0\)\
\-\ given\\:\\ 0\\.019499621081731863\ \(0\)\
\-\ benign\\:\\ 0\\.019472241983495925\ \(0\)\
\-\ neoplasm\\:\\ 0\\.01935086920963969\ \(0\)\
\-\ swelling\\:\\ 0\\.01907868861863411\ \(0\)\
\-\ type\\:\\ 0\\.01901602330195914\ \(0\)\
\-\ flow\\:\\ 0\\.018880879666948312\ \(0\)\
\-\ radiation\\:\\ 0\\.01878485167859398\ \(0\)\
\-\ vascular\\:\\ 0\\.018714029191101315\ \(0\)\
\-\ positive\\:\\ 0\\.018678992897250692\ \(0\)\
\-\ air\\:\\ 0\\.018541266933763803\ \(0\)\
\-\ between\\:\\ 0\\.018418286008579497\ \(0\)\
\-\ during\\:\\ 0\\.017954710858254293\ \(0\)\
\-\ age\\:\\ 0\\.017796313583435665\ \(0\)\
\-\ fat\\:\\ 0\\.01763337132152118\ \(0\)\
\-\ negative\\:\\ 0\\.017549223226460544\ \(0\)\
\-\ ultrasound\\:\\ 0\\.017484745850499354\ \(0\)\
\-\ abdomen\\:\\ 0\\.01729618633889036\ \(0\)\
\-\ month\\:\\ 0\\.017243600729036586\ \(0\)\
\-\ changes\\:\\ 0\\.017131539052509307\ \(0\)\
\-\ region\\:\\ 0\\.016955690596692073\ \(0\)\
\-\ edema\\:\\ 0\\.016906570324328137\ \(0\)\
\-\ all\\:\\ 0\\.016874091164528985\ \(0\)\
\-\ include\\:\\ 0\\.016866004435715804\ \(0\)\
\-\ been\\:\\ 0\\.01651508499968055\ \(0\)\
\-\ months\\:\\ 0\\.016500049303613387\ \(0\)\
\-\ blood\\:\\ 0\\.016462657902522656\ \(0\)\
\-\ cm\\:\\ 0\\.016279808218081886\ \(0\)\
\-\ high\\:\\ 0\\.016110384066435664\ \(0\)\
\-\ mild\\:\\ 0\\.016068915449493675\ \(0\)\
\-\ who\\:\\ 0\\.016034620670457418\ \(0\)\
\-\ over\\:\\ 0\\.015761989036733107\ \(0\)\
\-\ noted\\:\\ 0\\.015029357463053351\ \(0\)\
\-\ chest\\:\\ 0\\.014962803426816855\ \(0\)\
\-\ mri\\:\\ 0\\.014550659884603691\ \(0\)\
\-\ present\\:\\ 0\\.014545591762023592\ \(0\)\
\-\ lower\\:\\ 0\\.014485174072380879\ \(0\)\
\-\ may\\:\\ 0\\.014264932986849378\ \(0\)\
\-\ up\\:\\ 0\\.014022024409115368\ \(0\)\
\-\ surgical\\:\\ 0\\.013777401279594214\ \(0\)\
\-\ after\\:\\ 0\\.013751429301871726\ \(0\)\
\-\ female\\:\\ 0\\.01367857073591188\ \(0\)\
\-\ seen\\:\\ 0\\.01334537786632787\ \(0\)\
\-\ also\\:\\ 0\\.013333456324202958\ \(0\)\
\-\ which\\:\\ 0\\.012889508198617446\ \(0\)\
\-\ disease\\:\\ 0\\.011898920716456795\ \(0\)\
\-\ from\\:\\ 0\\.011258091456698016\ \(0\)\
\-\ an\\:\\ 0\\.010839667514618165\ \(0\)\
\-\ ct\\:\\ 0\\.010791839486515103\ \(0\)\
\-\ this\\:\\ 0\\.009740422752205307\ \(0\)\
\-\ right\\:\\ 0\\.00939809055514615\ \(0\)\
\-\ patient\\:\\ 0\\.009219745363762974\ \(0\)\
\-\ old\\:\\ 0\\.008389471123446126\ \(0\)\
